Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDI Calidi Biotherapeutics	$5.86 +10.8%	$5.50	$2.43 ▼ $46.68	$17.73M	1.15	645,531 shs	154,660 shs
IKT Inhibikase Therapeutics	$1.71 -2.3%	$1.80	$1.12 ▼ $4.20	$130.10M	0.9	195,907 shs	131,136 shs
PRME Prime Medicine	$3.81 +10.1%	$3.24	$1.11 ▼ $5.17	$512.43M	2.39	2.51 million shs	3.19 million shs
PRVL Prevail Therapeutics	$23.00	$23.01	$9.02 ▼ $23.35	$787.66M	1.59	955,800 shs	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDI Calidi Biotherapeutics	+4.96%	-27.03%	-42.00%	+10.21%	-74.81%
IKT Inhibikase Therapeutics	+15.89%	-2.78%	-5.41%	-17.45%	+32.58%
PRME Prime Medicine	-1.42%	-20.82%	-20.46%	+185.95%	-16.12%
PRVL Prevail Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDI Calidi Biotherapeutics	0.0931 of 5 stars	0.0	2.0	0.0	0.0	0.6	0.0	0.6
IKT Inhibikase Therapeutics	1.9516 of 5 stars	3.3	3.0	0.0	0.0	1.1	0.0	1.3
PRME Prime Medicine	3.5351 of 5 stars	4.4	1.0	0.0	0.0	1.6	5.0	0.6
PRVL Prevail Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDI Calidi Biotherapeutics	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	280.12% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	134.03% Upside
PRVL Prevail Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRVL, PRME, CLDI, and IKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50
5/20/2025	PRME Prime Medicine	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $6.00
5/20/2025	PRME Prime Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/20/2025	PRME Prime Medicine	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/19/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $12.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	($2.32) per share	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
PRME Prime Medicine	$4.96M	103.29	N/A	N/A	$1.37 per share	2.78
PRVL Prevail Therapeutics	N/A	N/A	N/A	N/A	$4.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A
PRVL Prevail Therapeutics	-$63.19M	-$2.22	N/A	N/A	N/A	N/A	-55.57%	-48.14%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	37.95%	N/A	N/A	N/A
PRVL Prevail Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
IKT Inhibikase Therapeutics	N/A	0.85	0.85
PRME Prime Medicine	N/A	6.50	6.50
PRVL Prevail Therapeutics	N/A	7.56	7.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDI Calidi Biotherapeutics	12.53%
IKT Inhibikase Therapeutics	3.81%
PRME Prime Medicine	70.37%
PRVL Prevail Therapeutics	86.80%

Insider Ownership

Company	Insider Ownership
CLDI Calidi Biotherapeutics	6.70%
IKT Inhibikase Therapeutics	7.30%
PRME Prime Medicine	22.74%
PRVL Prevail Therapeutics	57.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDI Calidi Biotherapeutics	38	3.03 million	20.04 million	N/A
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
PRME Prime Medicine	234	134.50 million	100.38 million	Optionable
PRVL Prevail Therapeutics	66	34.25 million	N/A	Not Optionable

PRVL, PRME, CLDI, and IKT Headlines

Recent News About These Companies

Prevail International On Track to Deliver State-of-the-Art Parirenyatwa Facilities

July 25, 2025 | msn.com

I Prevail Announce Fourth Studio Album, Reveal New Single ‘Rain’

July 19, 2025 | msn.com

How I Prevail’s Eric Vanlerberghe Learned to Do Clean Vocals

July 19, 2025 | msn.com

Ukraine's Skyeton and UK's Prevail Partners launch joint drone production

July 3, 2025 | msn.com

Brian Burkheiser Breaks Silence on I Prevail Split, Rallies Support for Band

July 2, 2025 | loudwire.comL

Prevail Therapeutics Inc (PRVL) Stock Forums - Investing.com

June 30, 2025 | investing.com

Prevail, Inc. receives $120K grant from Hamilton County Community Foundation

May 29, 2025 | readthereporter.comR

I Prevail Announce Split With Co-Vocalist Brian Burkheiser in New Statement

May 16, 2025 | msn.com

Prevail Bank donates to 29 charitable programs

April 29, 2025 | wausaupilotandreview.comW

Leawood-based Prevail launches $100M VC fund, makes first two investments

April 9, 2025 | bizjournals.com

Data supports Medtronic Prevail paclitaxel-coated balloon

March 10, 2025 | massdevice.com

Prevail Bank’s matching funds campaign garners more than $20K

December 30, 2024 | wausaupilotandreview.comW

Prevail provides holiday hope to 55 families who need it most

December 24, 2024 | msn.com

Prevail receives $10,000 gift from Elements Cares

December 11, 2024 | readthereporter.comR

I Prevail + Hollywood Undead SCREAM Through Haunted Blood Prison | Paranormal Prison

November 13, 2024 | msn.com

Prevail Bank launches Holiday Matching Funds campaign

November 7, 2024 | centralwinews.comC

How I Prevail and All Time Low teamed up to create their monster hit “Hate This Song”

November 4, 2024 | yahoo.com

Prevail Endowment receives $1M gift honoring Frank Pichler’s Legacy

November 1, 2024 | readthereporter.comR

Illinois Takes on the Ducks: Will Toughness Prevail?

October 25, 2024 | msn.com

Medtronic’s Prevail DCB pivotal trial receives FDA IDE approval

October 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRVL, PRME, CLDI, and IKT Company Descriptions

Calidi Biotherapeutics NYSE:CLDI

$5.86 +0.57 (+10.78%)

Closing price 04:00 PM Eastern

Extended Trading

$5.75 -0.11 (-1.88%)

As of 07:59 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Inhibikase Therapeutics NYSE:IKT

$1.71 -0.04 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$1.71 0.00 (0.00%)

As of 06:33 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Prime Medicine NYSE:PRME

$3.81 +0.35 (+10.12%)

Closing price 03:59 PM Eastern

Extended Trading

$3.81 0.00 (0.00%)

As of 07:37 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Prevail Therapeutics NASDAQ:PRVL

Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time